LLY

714.52

-4.44%↓

JNJ

146.39

-1.44%↓

UNH

308.04

-0.79%↓

ABBV

177.11

-5.79%↓

NVO

64.32

-1.7%↓

LLY

714.52

-4.44%↓

JNJ

146.39

-1.44%↓

UNH

308.04

-0.79%↓

ABBV

177.11

-5.79%↓

NVO

64.32

-1.7%↓

LLY

714.52

-4.44%↓

JNJ

146.39

-1.44%↓

UNH

308.04

-0.79%↓

ABBV

177.11

-5.79%↓

NVO

64.32

-1.7%↓

LLY

714.52

-4.44%↓

JNJ

146.39

-1.44%↓

UNH

308.04

-0.79%↓

ABBV

177.11

-5.79%↓

NVO

64.32

-1.7%↓

LLY

714.52

-4.44%↓

JNJ

146.39

-1.44%↓

UNH

308.04

-0.79%↓

ABBV

177.11

-5.79%↓

NVO

64.32

-1.7%↓

Search

Immunocore Holdings PLC ADR

Fermé

27.7 -2.43

Résumé

Variation du prix de l'action

24h

Actuel

Min

26.77

Max

28.23

Chiffres clés

By Trading Economics

Revenu

29M

5M

Ventes

9.8M

94M

BPA

-0.49

Marge bénéficiaire

5.35

Employés

493

EBITDA

13M

-3.6M

Recommandations

By TipRanks

Recommandations

Achat Fort

Prévisions sur 12 Mois

+122.21% upside

Dividendes

By Dow Jones

Prochains Résultats

7 août 2025

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

-19M

1.5B

Ouverture précédente

30.13

Clôture précédente

27.7

Score Technique

By Trading Central

Confiance

Weak Bearish Evidence

Immunocore Holdings PLC ADR Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

14 mai 2025, 23:40 UTC

Actions en Tendance

Stocks to Watch: UnitedHealth Group, Foot Locker, CoreWeave

14 mai 2025, 23:33 UTC

Principaux Mouvements du Marché

UnitedHealth Group Shares Fall After WSJ Reports of Investigation for Possible Medicare Fraud

14 mai 2025, 23:25 UTC

Principaux Mouvements du Marché

Biohaven Shares Down as FDA Extends PDUFA Data for Troriluzole

14 mai 2025, 23:25 UTC

Résultats

Xero Lifts Fiscal Year Profit 30% on Higher Prices, Subscriber Growth -- Update

14 mai 2025, 22:58 UTC

Résultats

Xero Lifts Fiscal Year Profit 30% on Higher Prices, Subscriber Growth

14 mai 2025, 21:35 UTC

Résultats

Cisco Systems Names Patterson as CFO, Patel as President

14 mai 2025, 23:59 UTC

Market Talk

Implications of Xero's Cost Outlook Aren't Clear -- Market Talk

14 mai 2025, 23:49 UTC

Market Talk

Xero's Cost Outlook Likely to Prompt Downgrades -- Market Talk

14 mai 2025, 23:48 UTC

Market Talk

Global Equities Roundup: Market Talk

14 mai 2025, 23:48 UTC

Market Talk

Nikkei May Decline on Profit-Taking After Recent Gains -- Market Talk

14 mai 2025, 23:47 UTC

Market Talk

Gold Gains on Possible Technical Recovery -- Market Talk

14 mai 2025, 23:34 UTC

Acquisitions, Fusions, Rachats

Agnico-Eagle Mines to Subscribe for 30M Voting Common Shares of Foran Mining in Non-Brokered Private Placement at C$3 a Share

14 mai 2025, 23:10 UTC

Résultats

Xero Lifts FY Profit 30% on Higher Prices, Subscriber Growth -- Update

14 mai 2025, 23:07 UTC

Résultats

CoreWeave Posts Strong Revenue and Wins Google as a Customer. Stock Still Dives on Outlook. -- Barrons.com

14 mai 2025, 23:00 UTC

Actualités

UnitedHealth Group Is Under Criminal Investigation for Possible Medicare Fraud -- WSJ

14 mai 2025, 22:43 UTC

Résultats

Xero Lifts FY Profit 30% on Higher Prices, Subscriber Growth

14 mai 2025, 22:34 UTC

Résultats

Xero Expects 1H Operating Expense Ratio to Be Higher Than 2H>XRO.AU

14 mai 2025, 22:33 UTC

Résultats

Xero Expects FY26 Operating Expense Ratio of 71.5%>XRO.AU

14 mai 2025, 22:30 UTC

Résultats

Xero Did Not Declare a Dividend>XRO.AU

14 mai 2025, 22:30 UTC

Résultats

Xero FY Operating Expenses 71.8% of Operating Revenue Vs. 73.3%>XRO.AU

14 mai 2025, 22:30 UTC

Résultats

Xero FY Free Cashflow Margin 24.1% Vs. 20.0%>XRO.AU

14 mai 2025, 22:30 UTC

Résultats

Xero FY Free Cashflow NZD506.7M Vs. NZD342.1M>XRO.AU

14 mai 2025, 22:28 UTC

Résultats

Xero FY Ebitda NZD638.5M Vs. NZD497.4M>XRO.AU

14 mai 2025, 22:28 UTC

Résultats

Xero FY Adjusted Ebitda NZD640.6M Vs. NZD526.5M>XRO.AU

14 mai 2025, 22:27 UTC

Résultats

Xero FY Rev NZD2.10B Vs. NZD1.71B >XRO.AU

14 mai 2025, 22:27 UTC

Résultats

Xero FY Net NZD227.8M Vs. Net NZD174.6M >XRO.AU

14 mai 2025, 22:23 UTC

Actualités

Boeing, GE Aerospace Get Qatar Airways Order After Saudi AI Tech Deals -- 2nd Update

14 mai 2025, 22:15 UTC

Résultats

Correction to Cisco Earnings Article -- WSJ

14 mai 2025, 21:48 UTC

Résultats

CoreWeave Posts Strong Revenue but Stock Dives on Updated Outlook -- Barrons.com

14 mai 2025, 21:37 UTC

Résultats

Cisco Reports Solid Earnings. The Stock Is Rising. -- Barrons.com

Comparaison

Variation de prix

Immunocore Holdings PLC ADR prévision

Objectif de Prix

By TipRanks

122.21% hausse

Prévisions sur 12 Mois

Moyen 65.64 USD  122.21%

Haut 100 USD

Bas 33 USD

Basé sur 11 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

11 ratings

9

Achat

2

Maintien

0

Vente

Score Technique

By Trading Central

27.895 / 30.16Support & Résistance

Court Terme

Weak Bearish Evidence

Moyen Terme

Weak Bearish Evidence

Long Terme

Weak Bearish Evidence

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Immunocore Holdings PLC ADR

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma. In addition, the company's product pipeline comprises IMC-F106C, which is in a Phase 3 clinical trial to treat first line advanced cutaneous melanoma; and in a Phase 1/2 clinical trial in multiple tumor types, such as platinum resistant ovarian, non-small cell lung, and endometrial carcinoma. Further, it develops IMC-R117C, which is in phase 1 clinical trial to treat colorectal and gastrointestinal cancers; IMC-M113V, which is in phase 1 clinical trial to treat human immunosuppression virus; IMC-I109V, which is in a Phase I clinical trial in patients with chronic hepatitis B virus; IMC-T119C, which is in preclinical trial for multiple solid tumor cancers; IMC-P115C, which is in preclinical trial to treat multiple solid tumor cancers; and IMC-S118AI to treat type 1 diabetes and is in preclinical trial. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.